Dan G. Hilton

1 month ago | mondaq.com | Graham Lewis |David Power |Dan G. Hilton

Welcome to the latest edition of the J A Kemp annual review ofEPO Board of Appeal decisions relating to antibody inventions. Thisyear we are reviewing decisions published between 31 January 2024and 31 December 2024. Overall, the majority of the decisionspublished in this interval followed current EPO examiner practicefor antibody inventions, as codified in the EPO's Guidelinesfor Examination (G-II, 6 – also discussed in our advanced guide).

May 8, 2024 | mondaq.com | Graham Lewis |Vicki Allen |Dan G. Hilton

Last year we provided a review of 19 EPO Board of Appeal decisions relating to "antibody inventions" that were published between January and December 2022. We have now reviewed the decisions published in 2023. Before discussing these decisions, we should first briefly mention G 2/21, which is a decision by the Enlarged Board of Appeal published in March 2023. G 2/21 considered whether post-published evidence could be used to prove the existence of a technical effect when assessing inventive step.

Apr 23, 2024 | lexology.com | Graham Lewis |Dan G. Hilton

This review will be of interest to USA patent professionals, companies, scientists, and inventors working in the antibody field. The US PTO and the EPO take very different approaches when considering antibody inventions, with the EPO’s approach being continuously developed by the case law of its Boards of Appeal.

Jul 21, 2023 | mondaq.com | Dan G. Hilton

Since the discovery of the structure of DNA, the accepted central dogma of molecular biology states that the genetic information contained in our DNA is transcribed into short-lived messenger RNA, which is translated into the proteins that carry out the vast majority of our cellular functions. Remarkably, all of our cells contain essentially the same DNA, but clearly cell types and functions differ.